By Andrew Silver SHANGHAI, June 29 (Reuters) - GLP-1 drugs from Pfizer and Innovent Biologics have passed a preliminary ...

Pfizer's GLP-1 drug showed 12% weight loss over six months with just one monthly injection. Experts say it could be years before it receives regulatory approval ...

Pfizer (PFE) announced early Monday that it is halting a late-stage trial of its GLP-1 pill candidate, danuglipron, dashing hopes of the company entering the obesity space in the near term. A trial ...

Pfizer (NYSE:PFE) has announced a new CFO transition as Dave Denton prepares to step down in August, adding another management change at a time when the drugmaker is still working to rebuild growth ...

BEIJING, June 29 () - Pfizer's ‌GLP-1 ‌drug Ecnoglutide and ​Innovent Biologics' mazdutide injection have passed ‌a ...

Pfizer stock (NYSE: PFE) currently trades at $29 per share, 45% below its peak level of $54 seen in December 2021. In contrast, Merck stock is up 54% over this period. PFE stock was trading at $47 in ...

Pfizer’s top cancer drugs are small molecules, but dealmaking has expanded the pharmaceutical giant’s portfolio and pipeline with biologic medicines. Its latest deal puts it in a camp of companies ...

Pfizer (NYSE:PFE) has quietly built momentum in 2026, with shares up 6.61% year-to-date and 2.70% over the past year. The stock is currently trading near $26.84 but remains well below its 52-week high ...